Scarica l'app Stockscreener
104.46
1.13%
-1.19
Pre-mercato:
104.45
-0.010
-0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$105.65
Aprire:
$106.45
Volume 24 ore:
932.39K
Relative Volume:
0.45
Capitalizzazione di mercato:
$20.51B
Reddito:
$4.58B
Utile/perdita netta:
$870.87M
Rapporto P/E:
23.75
EPS:
4.3988
Flusso di cassa netto:
$945.58M
1 W Prestazione:
+2.35%
1M Prestazione:
+13.98%
6M Prestazione:
+60.88%
1 anno Prestazione:
+38.45%
Intervallo 1D:
$103.85
$106.99
Intervallo di 1 settimana:
$102.50
$107.61
Portata 52W:
$53.56
$109.28
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Confronta INCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
104.46 | 20.74B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Sets December Investor Lineup as Pipeline Progress Draws Market Attention - MyChesCo
Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Incyte: This Profitable Biotech Trades Like A Melting Iceberg (NASDAQ:INCY) - Seeking Alpha
Incyte: Riding Jakafi, Bracing For Generic Headwinds (NASDAQ:INCY) - Seeking Alpha
Incyte’s principal accounting officer Tray Thomas sells $79k in stock - Investing.com
Incyte receives the first letter confirming compliance following the FDA’s Untitled Letter spree - Medical Marketing and Media
Opzelura From Incyte Corp. - Pharmacy Times
Incyte Corp. Stock Climbs 4.1%, Outperforms Peers - 富途牛牛
Integra LifeSciences, Evolent Health, Incyte, iRhythm, and Clover Health Stocks Trade Up, What You Need To Know - Yahoo Finance
Incyte (INCY): Barclays Raises Price Target to $115, Maintains Overweight Rating | INCY Stock News - GuruFocus
Does Incyte's Expanding Drug Pipeline Signal an Opportunity Following a 46.8% Price Surge? - Yahoo Finance
Incyte (INCY) Tops Goldman Sachs' Hedge Fund Concentration List - GuruFocus
Officer Tray Files To Sell 169 Of Incyte Corp [INCY] - TradingView
Commit To Purchase Incyte At $87.50, Earn 12.3% Annualized Using Options - Nasdaq
Is Incyte Corporation (ICY) stock among top earnings playsJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
Incyte to Present at Upcoming December 2025 Investor Conferences - BioSpace
Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Is Incyte Corporation (ICY) stock considered safe havenJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
Why Incyte (INCY) is a Top Value Stock for the Long-Term - Yahoo Finance
Incyte at Jefferies London: Strategic Shift to Diversification - Investing.com
Incyte Expands ‘Moments of Clarity’ With New Stories Spotlighting Chronic Skin Conditions - MyChesCo
Incyte Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
VP Denton Files To Sell 278 Of Incyte Corp [INCY] - TradingView
Is Incyte Corporation building a consolidation baseEarnings Recap Report & Verified Chart Pattern Signals - newser.com
Incyte (INCY) Receives Positive Opinion for Minjuvi in Europe - GuruFocus
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) - BioSpace
Incyte corp EVP Steven Stein sells shares worth $897,866 - MSN
Can Incyte Corporation (ICY) stock attract analyst upgradesEarnings Trend Report & Reliable Entry Point Trade Alerts - newser.com
Forecasting Incyte Corporation price range with options dataJuly 2025 Outlook & Fast Entry High Yield Tips - newser.com
STATE STREET CORP Reduces Stake in Incyte Corp: A Strategic Port - GuruFocus
What risks investors should watch in Incyte Corporation stockTreasury Yields & AI Powered Market Entry Ideas - newser.com
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte Corp. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Key metrics from Incyte Corporation’s quarterly dataJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Why Analysts See Incyte’s Story Shifting as Pipeline Progress Drives New Valuation Targets - Yahoo Finance
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Incyte Corporation stock see PE expansionQuarterly Growth Report & Weekly High Return Opportunities - newser.com
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte Prepares to Showcase Pipeline Momentum With New mutCALR Data at ASH 2025 - MyChesCo
Incyte (INCY): Exploring Valuation After Recent Share Price Rally and Pipeline Progress - Yahoo Finance
Incyte stock hits 52-week high at 108.81 USD By Investing.com - Investing.com Canada
Incyte stock hits 52-week high at 108.81 USD - Investing.com
Peering Into Incyte Corp's Recent Short Interest - Benzinga
Incyte Posts 20% Revenue Growth, Raises 2025 Outlook on Strong Drug Demand - MSN
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus - MyChesCo
The Bull Case For Incyte (INCY) Could Change Following Raised 2025 Guidance and Oncology Program Updates – Learn Why - simplywall.st
Prelude Strikes $910 Million Deal With Incyte for Groundbreaking JAK2 Cancer Therapy - MyChesCo
Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains - 富途牛牛
Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack - Yahoo Finance
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
0.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):